NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Friday, February 21st. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 annualized dividend and a dividend yield of 1.65%. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) released its earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.95. The healthcare product maker earned $8.31 billion during the quarter, compared to the consensus estimate of $8.26 billion. Abbott Laboratories had a return on equity of 18.34% and a net margin of 11.56%. Abbott Laboratories's revenue was up 7.1% on a year-over-year basis. During the same period last year, the firm earned $0.81 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, April 15th 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share (EPS) guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus estimate of $3.60.

18 equities research analysts have issued 12 month target prices for Abbott Laboratories' shares. Their forecasts range from $81.00 to $105.00. On average, they anticipate Abbott Laboratories' stock price to reach $95.79 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Press coverage about ABT stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave media headlines about the healthcare product maker a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Abbott Laboratories.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Home Depot (HD), NVIDIA (NVDA), Walt Disney (DIS), Verizon Communications (VZ), Pfizer (PFE) and Intel (INTC).

Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (6.43%), State Street Corp (4.16%), Capital International Investors (2.68%), Massachusetts Financial Services Co. MA (1.75%), Geode Capital Management LLC (1.41%) and FMR LLC (1.41%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, FIL Ltd, FMR LLC, Thrivent Financial for Lutherans, Janus Henderson Group PLC, Massachusetts Financial Services Co. MA, Bank of New York Mellon Corp and UBS Asset Management Americas Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was bought by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Wealth Quarterback LLC, Capital International Investors, State Street Corp, GQG Partners LLC, Capital Research Global Investors, Alliancebernstein L.P. and Milestone Resources Group Ltd. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $87.45.

Abbott Laboratories has a market capitalization of $154.65 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.